Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 337.2%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 240,900 shares, an increase of 337.2% from the March 31st total of 55,100 shares. Approximately 4.4% of the shares of the company are sold short. Based on an average daily trading volume, of 221,200 shares, the short-interest ratio is presently 1.1 days.

bioAffinity Technologies Trading Down 1.6 %

Shares of BIAF stock traded down $0.04 during trading hours on Thursday, hitting $2.41. The stock had a trading volume of 112,596 shares, compared to its average volume of 182,546. The stock’s 50 day moving average is $2.16 and its 200 day moving average is $1.71. bioAffinity Technologies has a twelve month low of $0.95 and a twelve month high of $3.62. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.77 and a quick ratio of 1.76.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings results on Monday, April 1st. The company reported ($0.26) EPS for the quarter. The company had revenue of $2.21 million for the quarter. bioAffinity Technologies had a negative return on equity of 107.20% and a negative net margin of 313.34%.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.